Abbott (ABT) recently received a CE Mark in Europe for the AVEIR dual chamber (DR) leadless pacemaker system, the first ever dual chamber leadless pacemaker that treats people with abnormal or slow heart rhythms. The news follows the system’s FDA approval in June last year, shortly after late-breaking clinical data revealed that the AVEIR DR system met its three prespecified primary endpoints for safety and efficacy. The latest development is expected to significantly boost the company’s Cardiac Rhythm Mana ...

文章核心观点 - 艾伯特公司宣布其两款葡萄糖监测系统Lingo和Libre Rio获得FDA批准 [1] - Lingo和Libre Rio基于艾伯特公司自有的FreeStyle Libre持续性葡萄糖监测(CGM)技术 [1][2] - 这一最新发展有望扩大公司的糖尿病护理业务 [1] 关于Lingo - Lingo面向18岁及以上消费者,旨在帮助他们更好地了解自身的代谢健康,并提供个性化建议以促进生活方式改变 [2][3] - 根据北卡罗来纳大学的一项研究,只有12%的美国人代谢健康,这反映了Lingo巨大的市场潜力 [4] - 82%的美国人希望借助生物可穿戴设备如Lingo改变生活方式 [5] 关于Libre Rio - Libre Rio是艾伯特公司Libre CGM系统系列产品之一,面向18岁及以上2型糖尿病成人,旨在通过生活方式改变而非使用胰岛素来改善健康状况 [6] - Libre Rio无需处方,更加用户友好,有望获得巨大的市场接受度 [6][8] - 美国有近3840万人患有糖尿病,这是一个巨大的市场 [7] 行业前景 - 根据Future Market Insights的报告,全球CGM系统市场规模将从2023年的111亿美元增长到2033年的1035亿美元,年复合增长率为25.1% [10] - 主要推动因素包括全球糖尿病患病率上升、技术进步以及CGM系统的用户友好性、可靠性和准确性 [10] 其他最新进展 - 2024年6月,艾伯特公司的AVEIR DR双腔无导线起搏器系统获得欧洲CE认证 [11] - 2024年4月,艾伯特公司的Esprit BTK依维莫司可吸收支架系统获得FDA批准,这是美国首次批准用于膝关节以下的设备 [12] 股价表现 - 过去一年,艾伯特公司股价上涨4.3%,而行业平均上涨3.6% [13]

They both have pretty impressive pasts, and their prospects look just as bright. We're almost halfway through the year, and so far, it's been a pretty solid one for equity markets. It's as good a time as any to review one's portfolio and potentially consider putting more money into stocks with the understanding that our current bull market won't last forever. So, as always, it's essential to invest in stocks that can perform well over long periods, regardless of how they may be doing right now. For those wh ...

文章核心观点 - 艾伯特公司获得美国FDA批准推出两款新的连续血糖监测系统,包括一款面向非糖尿病人群的产品 [2] - 这些新系统可以在无需处方的情况下直接面向消费者销售 [2][7] - 这些新产品有望大幅扩展公司的市场机会,因为美国有3840万人患有糖尿病,而公司现有CGM产品已经在60个国家被600万患者使用 [4] - 公司推出的Libre Rio产品针对2型糖尿病但不需要胰岛素治疗的患者,Lingo产品则面向希望改善健康和代谢的普通消费者 [5][6] 公司相关 - 艾伯特公司现有CGM产品已经在60个国家被600万患者使用 [4] - 公司推出的Libre Rio产品针对2型糖尿病但不需要胰岛素治疗的患者 [8] - 公司推出的Lingo产品面向希望改善健康和代谢的普通消费者 [6] - 公司的新产品可以在无需处方的情况下直接面向消费者销售 [2][7] 行业相关 - 美国有3840万人患有糖尿病,这为公司新产品带来了巨大的市场机会 [4] - 其他公司如Signos也在利用CGM技术帮助人们减重和改善代谢健康 [6] - 竞争对手Dexcom公司也获得FDA批准推出了首款面向消费者的CGM产品 [9]

Abbott's consumer biowearable, Lingo™, is designed for general consumers who are looking to improve their overall health and wellness Libre Rio™ is designed for adults with Type 2 diabetes who do not use insulin and typically manage their diabetes through lifestyle modifications Both products are based on FreeStyle Libre® sensing technology, the world's most widely used1 continuous glucose monitoring (CGM) systems, pioneered by Abbott and used by about 6 million people globally2 ABBOTT PARK, Ill., June 10, ...

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell- side) analysts often affect a stock's price, do they really matter? Let's take a look at what these Wall Street heavyweights have to say about Abbott (ABT) before we discuss the reliability of brokerage recommendations and how to use them to your advantage. Abbott currently has an average brokerage ...

Abbott (ABT) closed the most recent trading day at $103.23, moving -0.19% from the previous trading session. This move lagged the S&P 500's daily gain of 1.19%. Meanwhile, the Dow gained 0.25%, and the Nasdaq, a tech-heavy index, added 1.96%. The the stock of maker of infant formula, medical devices and drugs has fallen by 2.58% in the past month, lagging the Medical sector's gain of 3.54% and the S&P 500's gain of 3.35%. The investment community will be closely monitoring the performance of Abbott in its f ...

Sundry Photography ABT stock: Wall Street loves it Readers following our writing know that we are contrarian investors and we usually bet against Wall Street ratings. However, in the case of Abbott Laboratories (NYSE:ABT) stock, we found ourselves in agreement with Wall Street. More specifically, the chart below summarizes the current sentiment on ABT stock from Wall Street analysts (and Seeking Alpha writers too). As seen, Wall Street analysts have a 'strong buy' rating on the stock, with 12 out of 24 anal ...

文章核心观点 - 联邦储备局可能降息,这对于可靠的股息股来说是利好消息 [1] - 但就业市场数据显示经济基本面保持强劲,这可能导致通胀上升,不利于降息 [2] - 同时地缘政治局势不确定性加剧,可能导致投资者转向避险资产政府债券,从而使股息股更具吸引力 [3] 行业和公司总结 医疗保健行业 - 雅培实验室(ABT)是全球最大的医疗设备企业之一,提供广泛的医疗产品和服务,股息收益率为2.12% [5][6][7][8] - 美敦力(MDT)是医疗设备领域的大型企业,股息收益率为3.4%,连续47年增加派息 [27][28][29] 零售行业 - 克罗格(KR)是大型连锁超市,在经济不确定时期具有防御性,股息收益率为2.19%,连续18年增加派息 [10][11][12][13] - 家得宝(HD)是家居装修零售商,在房地产需求增加时受益,股息收益率为2.77%,连续15年增加派息 [14][15][16][17] 电信行业 - 康卡斯特(CMCSA)是大型媒体和电信公司,受益于旅游业复苏,股息收益率为3.22% [19][20][21][22] 公用事业行业 - 森宝(SRE)是多元化公用事业公司,主要服务于加州南部地区,股息收益率为3.27%,连续21年增加派息 [23][24][25][26] 能源行业 - 金德摩根(KMI)是能源管道和终端运营商,尽管面临清洁能源转型,但仍具有长期价值,股息收益率为6.03% [30][31][32][33]

The bull market continues; markets quickly dusted off the 5% correction in April and soared to new highs. With too much cash on the sidelines, every shallow correction has become a buying opportunity. Blue-chip stocks are one way to play this positive momentum. From a historical perspective, the markets are in great shape for continued gains. In the first 100 trading days of 2024, the S&P 500 has had about a 10% gain. JPMorgan Wealth Management noted that since 1950, that has meant a stronger second half, w ...